About Avenue Therapeutics (NASDAQ:ATXI)
Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31, 2016, the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions
What is Avenue Therapeutics' stock symbol?
Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."
How were Avenue Therapeutics' earnings last quarter?
Avenue Therapeutics Inc (NASDAQ:ATXI) issued its quarterly earnings results on Thursday, November, 9th. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.05. View Avenue Therapeutics' Earnings History.
Who are some of Avenue Therapeutics' key competitors?
Some companies that are related to Avenue Therapeutics include Cardiome Pharma (CRME), VIVUS (VVUS), Ocera Therapeutics (OCRX), Opiant Pharmaceuticals (OPNT), Chiasma (CHMA), Cesca Therapeutics (KOOL), Novus Therapeutics (NVUS), Sonoma Pharmaceuticals (SNOA), Onconova Therapeutics (ONTX), Argos Therapeutics (ARGS), Ambit Biosciences (AMBI), Baxalta (BXLT), Optimer Pharmaceuticals (OPTR), Transition Therapeutics (TTHI) and Trius Therapeutics (TSRX).
When did Avenue Therapeutics IPO?
(ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.
When did Avenue Therapeutics' lock-up period expire?
Avenue Therapeutics' lock-up period expired on Monday, December 25th. Avenue Therapeutics had issued 5,500,000 shares in its IPO on June 27th. The total size of the offering was $33,000,000 based on an initial share price of $6.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.
How do I buy Avenue Therapeutics stock?
Shares of Avenue Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avenue Therapeutics' stock price today?
One share of Avenue Therapeutics stock can currently be purchased for approximately $3.80.
How big of a company is Avenue Therapeutics?
Avenue Therapeutics has a market capitalization of $39.52 million. Avenue Therapeutics employs 3 workers across the globe.
How can I contact Avenue Therapeutics?
Avenue Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Avenue Therapeutics (ATXI)MarketBeat's community ratings are surveys of what our community members think about Avenue Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Avenue Therapeutics (NASDAQ:ATXI) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Avenue Therapeutics (NASDAQ:ATXI) Earnings History and Estimates Chart
Avenue Therapeutics (NASDAQ ATXI) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Avenue Therapeutics (NASDAQ:ATXI) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Avenue Therapeutics (NASDAQ:ATXI)
No dividend announcements for this company have been tracked by MarketBeat.com
Avenue Therapeutics (NASDAQ ATXI) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 1.36%
Avenue Therapeutics (NASDAQ ATXI) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/17/2017||Neil Herskowitz||Director||Buy||1,000||$5.01||$5,010.00|| |
|10/9/2017||Neil Herskowitz||Director||Buy||500||$5.24||$2,620.00|| |
Avenue Therapeutics (NASDAQ ATXI) News Headlines
Avenue Therapeutics (NASDAQ:ATXI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Avenue Therapeutics (NASDAQ:ATXI) Income Statement, Balance Sheet and Cash Flow Statement
Avenue Therapeutics (NASDAQ ATXI) Stock Chart for Tuesday, January, 23, 2018